210 related articles for article (PubMed ID: 33328285)
1. Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes.
Svehlikova E; Mursic I; Augustin T; Magnes C; Gerring D; Jezek J; Schwarzenbacher D; Ratzer M; Wolf M; Howell S; Zakrzewski L; Urschitz M; Tschapeller B; Gatschelhofer C; Feichtner F; Lawrence F; Pieber TR
Diabetes Care; 2021 Feb; 44(2):448-455. PubMed ID: 33328285
[TBL] [Abstract][Full Text] [Related]
2. Fast-acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart.
Shiramoto M; Nishida T; Hansen AK; Haahr H
J Diabetes Investig; 2018 Mar; 9(2):303-310. PubMed ID: 28556616
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.
Heise T; Zijlstra E; Nosek L; Rikte T; Haahr H
Diabetes Obes Metab; 2017 Feb; 19(2):208-215. PubMed ID: 27709762
[TBL] [Abstract][Full Text] [Related]
4. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes.
Heise T; Pieber TR; Danne T; Erichsen L; Haahr H
Clin Pharmacokinet; 2017 May; 56(5):551-559. PubMed ID: 28205039
[TBL] [Abstract][Full Text] [Related]
5. Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart.
Pieber TR; Svehlikova E; Brunner M; Halberg IB; Due Thomsen KM; Haahr H
Diabetes Obes Metab; 2019 Sep; 21(9):2068-2075. PubMed ID: 31069935
[TBL] [Abstract][Full Text] [Related]
6. Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus.
Haahr H; Pieber TR; Mathieu C; Gondolf T; Shiramoto M; Erichsen L; Heise T
Clin Pharmacokinet; 2019 May; 58(5):639-649. PubMed ID: 30402720
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.
Heise T; Hövelmann U; Zijlstra E; Stender-Petersen K; Jacobsen JB; Haahr H
Drugs Aging; 2017 Jan; 34(1):29-38. PubMed ID: 27873152
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
[TBL] [Abstract][Full Text] [Related]
9. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
Heise T; Hövelmann U; Brøndsted L; Adrian CL; Nosek L; Haahr H
Diabetes Obes Metab; 2015 Jul; 17(7):682-8. PubMed ID: 25846340
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.
Heise T; Eckers U; Kanc K; Nielsen JN; Nosek L
Diabetes Technol Ther; 2008 Dec; 10(6):479-85. PubMed ID: 19049377
[TBL] [Abstract][Full Text] [Related]
11. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
12. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.
Fath M; Danne T; Biester T; Erichsen L; Kordonouri O; Haahr H
Pediatr Diabetes; 2017 Dec; 18(8):903-910. PubMed ID: 28165180
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People With Type 1 Diabetes.
Svehlikova E; Ashcroft NL; Gatschelhofer C; Gerring D; Höller V; Jezek J; Lackner B; Lawrence F; Pillai V; Ratzer M; Urschitz M; Wolf M; Pieber TR
Diabetes Care; 2023 Apr; 46(4):757-764. PubMed ID: 36710473
[TBL] [Abstract][Full Text] [Related]
14. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart.
Basu A; Pieber TR; Hansen AK; Sach-Friedl S; Erichsen L; Basu R; Haahr H
Diabetes Obes Metab; 2018 Jul; 20(7):1615-1622. PubMed ID: 29493118
[TBL] [Abstract][Full Text] [Related]
15. The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetes.
Biester T; von dem Berge T; Bendtsen LQ; Bendtsen MD; Rathor N; Danne T; Haahr H
Pediatr Diabetes; 2020 Aug; 21(5):781-790. PubMed ID: 32306477
[TBL] [Abstract][Full Text] [Related]
16. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
Haahr H; Sasaki T; Bardtrum L; Ikushima I
J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
[TBL] [Abstract][Full Text] [Related]
17. [The Pharmacokinetics, Pharmacodynamics and Bioequivalence of Insulin Aspart Produced by the United Laboratories Evaluated by Euglycemic Clamp Study].
Yu HL; Liu H; Li JQ; Tan HW; Yu YR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):397-402. PubMed ID: 32543150
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.
Heise T; Stender-Petersen K; Hövelmann U; Jacobsen JB; Nosek L; Zijlstra E; Haahr H
Clin Pharmacokinet; 2017 Jun; 56(6):649-660. PubMed ID: 27878566
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30).
Bott S; Tusek C; Heinemann L; Friberg HH; Heise T
Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):545-50. PubMed ID: 16235159
[TBL] [Abstract][Full Text] [Related]
20. The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes.
Krones R; Schütte C; Heise T
Diabetes Obes Metab; 2009 Jan; 11(1):41-4. PubMed ID: 19120432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
